Teleflex Inc. will be showcasing three Arrow-branded products in preparation for international launch, part of its peripherally inserted central catheter and jugular axillo-central catheter product lines that feature antithrombogenic and antimicrobial Chlorag+ard technology.
In studies, Chlorag+ard technology was shows to provide antithrombogenic (92 percent reduction in thrombus accumulation on catheter surfaces on an in vivo ovine model when challenged with Staphylococcus aureus) and antimicrobial properties (99.99 percent colonization reduction in gram +, gram – bacteria and fungal pathogens in an in vitro study), reduced thrombotic occlusion and a reduction in phlebitis and intimal hyperplasia (an average of 72 percent less intimal hyperplasia).
The catheters with the antithrombogenic and antimicrobial technology provide protection for at least 30 days, according to the company.
The company’s Arrow VPS Rhythm system, which is currently under review for CE mark and can be used in combination with all types of central venous access, provides ECG-based tip confirmation in a portable, lightweight design. It assists in placement and confirmation of the catheter tip in the superior vena cava-cavoatrial junction, and may be used with a range of catheter types, the company said.
When paired with additional technology in the Arrow product line, the system provides real-time catheter navigation and ECG-based tip positioning, with a visual blue line that tracks along the catheter pathway, according to the company.
The products will be showcased at the World Congress of Vascular Access conference, June 22-24, in Lisbon, Portugal.
